Building Adaptive Coping and Knowledge to Improve Daily Life (Back2Life): A Pilot Feasibility Clinical Trial for Youth With Chronic Sickle Cell Pain

About the study

The purpose of this study is to find out how teenagers with chronic pain and sickle cell disease respond to a new training program called Back2Life and get their feedback about how to modify the program to best fit their needs. The Back2Life training program focuses on teaching pain coping skills (also known as cognitive-behavioral therapy). The program teaches skills and strategies that may help teens improve chronic pain management and get back into their everyday activities.

Study point of contact

Soumitri Sil, PhD
[email protected]


10 Years - 18 Years


Not Applicable

Study type






participation requirements

for Youth:

diagnosed with SCD (any genotype)
report chronic pain
speak and read English
have not initiated new disease modifying-treatments (e.g, hydroxyurea, Endari, voxelotor, crizanlizumab, chronic transfusions) or significantly increased dosages of any disease-modifying treatments in the past 3 months

Inclusion Criteria for Parents or Caregivers:

speak and read English

participation restrictions

for Youth:

have comorbid medical conditions typically associated with pain but unrelated to SCD (e.g., rheumatologic disorders or inflammatory bowel disease)
are receiving chronic transfusion indicated for central nervous system risks and/or complications, previous overt strokes, or significant cognitive or developmental limitations, as per their healthcare provider or parent, that would impair completion of self-report measures or engagement in treatment sessions
received ≥ 3 sessions of outpatient psychological therapy for pain management in the 6 months prior to screening

Exclusion Criteria for Parents or Caregivers:

have significant cognitive limitations or severe psychiatric conditions, as per the child’s healthcare team or history, that would impair completion of self-report measures or engagement in treatment sessions

Last updated 2022-09-20